Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Thomason

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 3, 2020
Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the futureNathan Kapata, Chikwe Ihekweazu, Francine Ntoumi, et al.
Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
Contemporary Clinical Trials|April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 yearsAnna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV|April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trialAdeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
The New England Journal of Medicine|March 9, 2022
Shorter Treatment for Nonsevere Tuberculosis in African and Indian ChildrenAnna Turkova, Genevieve H Wills, Eric Wobudeya, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 3, 2020
Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the futureNathan Kapata, Chikwe Ihekweazu, Francine Ntoumi, et al.
Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.
Contemporary Clinical Trials|April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 yearsAnna Turkova, Man K Chan, Cissy Kityo, et al.
The Lancet. HIV|April 10, 2026
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trialAdeodata R Kekitiinwa, Angus Jennings, Mutsa Bwakura-Dangarembizi, et al.
The New England Journal of Medicine|March 9, 2022
Shorter Treatment for Nonsevere Tuberculosis in African and Indian ChildrenAnna Turkova, Genevieve H Wills, Eric Wobudeya, et al.
Pageof 16